cbdMD (YCBD) EBIT Margin (2016 - 2026)

cbdMD (YCBD) posted EBIT Margin of 5.71% for Q4 2025, up 60.72% sequentially from 14.53% in Q3 2025, and down 402.0% YoY from 1.89% in Q4 2024.

cbdMD (YCBD) EBIT Margin (2016 - 2026) Analysis & Trends

cbdMD has reported EBIT Margin for 10 years, with the latest figure at 5.71% in Q4 2025.

Quarterly EBIT Margin fell 402.0% year-over-year to 5.71% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 12.37% (down 49.0% YoY) and the FY2025 annual result came in at 11.27%, up 537.0% from the prior year.
EBIT Margin climbed to 5.71% in Q4 2025 per YCBD's latest filing, from 14.53% in the prior quarter.
Over five years, EBIT Margin peaked at 1.69% in Q4 2024 and troughed at 385.51% in Q2 2022.
A 5-year average of 77.97% and a median of 31.63% in 2023 frame the typical range for EBIT Margin.
The sharpest annual moves came in 2022 and 2023: EBIT Margin slumped 32671 bps in 2022, then surged 35571 bps in 2023.
Over 5 years, EBIT Margin stood at 255.1% in 2021, then jumped by 75 bps to 64.84% in 2022, then jumped by 69 bps to 19.83% in 2023, then soared by 91 bps to 1.69% in 2024, then plunged by 238 bps to 5.71% in 2025.
According to Business Quant data, EBIT Margin over the past three periods registered 5.71%, 14.53%, and 19.64% for Q4 2025, Q3 2025, and Q2 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBIT Margin (Qtr)
1	Haleon	44.51 Bn	43.55 Bn	-	-
2	Teva Pharmaceutical Industries	43.52 Bn	39.86 Bn	2.15 Bn	-5.58%
3	Zoetis	32.43 Bn	30.75 Bn	1.05 Bn	33.91%
4	Takeda Pharmaceutical	28.63 Bn	22.83 Bn	5.10 Bn	16.51%
5	United Therapeutics	21.87 Bn	19.21 Bn	683.80 Mn	42.23%
6	Viatris	18.98 Bn	18.09 Bn	1.46 Bn	0.17%
7	Neurocrine Biosciences	15.43 Bn	15.04 Bn	935.80 Mn	15.80%
8	Elanco Animal Health	12.02 Bn	11.49 Bn	798.00 Mn	18.13%
9	Dr Reddys Laboratories	10.14 Bn	9.98 Bn	-	-
10	cbdMD	5.41 Mn	3.29 Mn	3.04 Mn	-20.36%

Download Data